Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a formidable global health issue, with its incidence climbing at an alarming rate, particularly across China’s vast population. This condition, marked by excessive fat accumulation in liver cells, is closely linked to metabolic disorders such as obesity, insulin resistance, and type 2 diabetes — all of which synergize to exacerbate hepatic injury and drive disease progression. Given the complex interplay of metabolic and molecular factors governing MASLD pathogenesis, identifying precise molecular targets remains a high priority for researchers aiming to develop effective diagnostics and therapeutics.
In an illuminating publication dated March 16, 2026, the Chinese Medical Journal unveiled groundbreaking research conducted by a distinguished team from Shandong First Medical University. Their investigative efforts focused on deciphering the role of circulating exosomal microRNAs (miRNAs), a class of small non-coding RNAs known to modulate gene expression post-transcriptionally, in MASLD pathophysiology. By zeroing in on exosomal miRNAs, which circulate stably in the bloodstream enveloped within extracellular vesicles, the researchers sought to uncover novel biomarkers and mechanistic pathways underpinning metabolic steatosis.
The study design involved collecting plasma from a carefully matched cohort comprising six patients diagnosed with MASLD and six healthy volunteers. Employing sophisticated isolation techniques, the team extracted and characterized exosomes from these plasma samples. Subsequent high-throughput miRNA expression profiling identified two microRNAs—miR-122-3p and miR-3614-5p—that were significantly upregulated in the plasma exosomes of MASLD patients relative to healthy controls. This observation pointed toward their potential role as circulating indicators of liver metabolic dysfunction.
To interrogate the functional relevance of these candidates, the investigators employed well-established hepatocellular carcinoma cell lines HepG2 and Bel-7404, mimicking lipid-overloaded liver conditions by treating cells with oleic acid. Intriguingly, only miR-122-3p overexpression recapitulated key MASLD hallmarks, namely enhanced intracellular triglyceride accumulation and elevated generation of reactive oxygen species (ROS). These pathological features underscore mitochondrial stress and lipid toxicity, critical factors in MASLD progression. Furthermore, exosomes engineered to overexpress miR-122-3p similarly induced these deleterious effects within recipient hepatocytes, strongly implicating this miRNA as a driver of metabolic liver injury.
Pivoting toward mechanistic insights, the research team explored downstream molecular targets modulated by miR-122-3p. Using luciferase reporter assays, a gold standard for validating miRNA-mRNA interactions, fibroblast growth factor receptor 4 (FGFR4) emerged as a direct target suppressed by miR-122-3p binding to its 3’ untranslated region. FGFR4 is a critical receptor tyrosine kinase that influences hepatic lipid metabolism, cell proliferation, and energy homeostasis. Upon overexpression of miR-122-3p, FGFR4 protein levels were markedly diminished, perturbing its physiological signaling.
The repression of FGFR4 by miR-122-3p set off a cascade of metabolic dysregulation. One downstream consequence was the inhibition of adenosine 5′-monophosphate-activated protein kinase (AMPK) activity, a pivotal energy sensor and regulator that orchestrates cellular metabolism to mitigate steatosis. AMPK activation enhances fatty acid oxidation and limits lipogenesis, protecting hepatocytes from lipid overload. The dampening of AMPK signaling by miR-122-3p-mediated FGFR4 suppression thus disrupted metabolic equilibrium, fostering lipid deposition and oxidative damage.
In a compelling rescue experiment, forced overexpression of FGFR4 in the presence of elevated miR-122-3p reversed the metabolic impairments seen in hepatocytes, including diminished triglyceride accumulation, reduced oxidative stress markers, and restored AMPK phosphorylation. These results robustly validate the miR-122-3p/FGFR4/AMPK axis as a central molecular pathway orchestrating MASLD pathogenesis.
From a translational perspective, the identification of circulating exosomal miR-122-3p as a biomarker offers a promising non-invasive tool for MASLD diagnosis, monitoring, and potentially prognosis. Unlike invasive liver biopsies, plasma exosome profiling can facilitate early detection and patient stratification with minimal risk. Moreover, targeting this miRNA or its downstream effectors such as FGFR4 opens exciting therapeutic avenues. Future pharmacological or genetic interventions designed to modulate this axis may effectively halt or reverse liver steatosis and prevent progression to advanced fibrosis or cirrhosis.
Nevertheless, the authors emphasize that these findings, derived from a relatively small sample size and in vitro models, warrant validation in larger, diverse clinical cohorts. Comprehensive investigations encompassing longitudinal studies and multi-omics integration will be vital to fully elucidate the mechanistic nuances and therapeutic potential of targeting the miR-122-3p/FGFR4/AMPK pathway.
This landmark study not only advances our molecular understanding of MASLD but also spotlights extrinsic exosomal miRNA communication as a critical player in metabolic liver disease. As the global burden of MASLD continues to escalate, especially in rapidly modernizing societies, such insights are indispensable for pioneering personalized medicine approaches to combat this insidious epidemic.
In summary, the research highlights exosomal miR-122-3p as a potent modulator of hepatic lipid metabolism by directly targeting FGFR4 and subsequently impeding AMPK-dependent protective signaling. This newly identified molecular axis underpins critical pathogenic mechanisms in MASLD and unveils novel biomarker and therapeutic targets. The convergence of exosome biology and metabolic regulation heralds a new era in understanding and managing fatty liver diseases with immense clinical implications.
Subject of Research: People
Article Title: Effect of circulating exosomal miRNA-122-3p on metabolic dysfunction-associated steatotic liver disease through impairing FGFR4 expression
News Publication Date: 16-Mar-2026
Web References: http://dx.doi.org/10.1097/cm9.0000000000004003
References: 10.1097/cm9.0000000000004003
Keywords: Metabolism, Metabolic health, Metabolic networks, Metabolic pathways, Glycolytic pathway, Lipid metabolism, Liver, Diseases and disorders, Liver damage, Cell pathology, Cells, Live cells, Metabolic disorders, Fatty liver disease, Steatohepatitis, Fibroblasts
Tags: circulating exosomal microRNAs in metabolic disordersexosomal miR-122-3p in liver diseaseextracellular vesicles in liver disease diagnosticsMASLD and insulin resistance mechanismsmetabolic dysfunction-associated steatotic liver disease biomarkersmetabolic steatosis molecular targetsmiRNA role in MASLD pathogenesismiRNA-based therapeutic targets for MASLDnon-coding RNA regulation in liver metabolismobesity-related hepatic fat accumulationplasma exosome isolation techniquesShandong First Medical University MASLD
